QIAGEN Adds HGMD and Other BIOBASE Offerings, Plans Ingenuity Clinical

By Bio-IT World Staff 

 

May 21, 2014 | Yesterday, QIAGEN announced that it is adding content from BIOBASE including HGMD, the human gene mutation database, to its bioinformatics offerings. HGMD and other BIOBASE solutions will provide the foundation for Ingenuity Clinical, QIAGEN's forthcoming clinical NGS decision-support solution. 

 

"With HGMD and other content from BIOBASE, a respected organization with a dedicated team and robust line of unique databases and software, QIAGEN is further extending its competitive advantage as the overall market leader for clinical interpretation of human sequencing data," said Peer M. Schatz, CEO of QIAGEN in a press release. "…HGMD is a unique fit with our offering and will integrate well. We expect to drive additional adoption of this leading literature-based knowledge base used by clinical reference labs for annotating hereditary variants, as well as BIOBASE' other solutions by having integrated them into interpretation solutions shared with our Ingenuity Knowledge Base—adding value for QIAGEN and BIOBASE customers and accelerating our growth drivers in NGS and bioinformatics."

 

QIAGEN has been working to expand its product line over the past year, having acquired Ingenuity and CLC bio in 2013. The company plans to continue to market BIOBASE products on a standalone basis, and integrate products into QIAGEN's expanding Ingenuity Knowledge Base and the QIAGEN bioinformatics solutions that draw upon it. HGMD, which includes human inherited disease mutations, is already available to customers of QIAGEN's Ingenuity Variant Analysis (see, “As Genetics Moves to the Clinic, Pathogenic Variants Still Subject to Doubt and Debate”). QIAGEN expects to also include PGMD, the PharmacoGenomic Mutation Database, which seeks to identify all published gene variants that have been shown to affect drug response in patients.

 

QIAGEN’s planned Ingenuity Clinical product will be a Web-based solution to deliver faster, easier-to-use and high-confidence clinical interpretation and reporting of insights from NGS-based tests. More than 20 clinical testing laboratories are taking part in an early access program for Ingenuity Clinical, which is specifically designed to address challenges of scale, speed and decision support for healthcare laboratories adopting NGS. 

 

Free academic versions of HGMD and PGMD as well as other BIOBASE products such as Proteome and Transfac will remain available at http://www.biobase-international.com/products .